Dual-mode CRISPRa/i for genome-scale metabolic rewiring in Escherichia coli
Nucleic Acids Research · 11.08.2025 · 53 (15)
DOI: 10.1093/nar/gkaf818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 21.08.2025. Verfasst von Soo Young Moon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. Hauptthemen laut MEDLINE: Escherichia coli, CRISPR-Cas Systems, Escherichia coli Proteins, Metabolic Engineering. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, National Research Foundation, Republic of Korea: Bio & Medical Technology Development Program.
Abstract (Originalsprache)
CRISPR (clustered regularly interspaced palindromic repeats)-mediated transcriptional regulation is a powerful and programmable approach for controlling gene expression. While CRISPR-based gene repression is well established in bacteria, simultaneous activation and repression remain challenging due to the limited availability of effective bacterial activation domains. Here, we provide an efficient dual-mode CRISPR activation and interference (CRISPRa/i) system that integrates an evolved protospacer adjacent motif (PAM)-flexible dxCas9 with an engineered Escherichia coli cAMP receptor protein (CRP). Through systematic optimization of the CRP domains and linkers, we developed a versatile effector capable of precise gene expression control when combined with dxCas9. Our dxCas9–CRP system demonstrated robust activation of upstream regulatory regions and effective repression of coding sequences, enabling targeted and programmable gene regulation. Using dual-fluorescent reporters, we validated the ability of this system to concurrently regulate multiple genes. Furthermore, with pooled guide RNA libraries, we applied the dxCas9–CRP system to increase violacein production in E. coli via genome-scale activation and repression in a coordinated manner, successfully identifying key regulatory targets that significantly increase production. Overall, this dual-mode CRISPRa/i system advances the potential for bacterial metabolic pathway rewiring, providing precise and flexible control for a wide range of biotechnological applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
- Division of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang, Gyeongbuk 37673, Republic of Korea.
- Research Center for Bio-Based Chemistry, Korea Research Institute of Chemical Technology (KRICT), Ulsan 44429, Republic of Korea.
- Graduate School of Engineering Biology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
ORCID-Profile: Ju Young Lee
Förderung
- Ministry of Science and ICT
- National Research Foundation
- Republic of Korea: Bio & Medical Technology Development Program
- Artificial Cellular Organelles Project
- Korea-US Collaborative Research Fund (KUCRF)
- MSIT and the Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Moon, S. Y., Kim, M. R., An, N. Y., Noh, M. H., & Lee, J. Y. (2025). Dual-mode CRISPRa/i for genome-scale metabolic rewiring in Escherichia coli. Nucleic Acids Research, 53(15). https://doi.org/10.1093/nar/gkaf818
Vancouver
Moon SY, Kim MR, An NY, Noh MH, Lee JY. Dual-mode CRISPRa/i for genome-scale metabolic rewiring in Escherichia coli. Nucleic Acids Research. 2025;53(15). doi:10.1093/nar/gkaf818
BibTeX
@article{Moon2025,
author = {Moon, Soo Young and Kim, Mi Ri and An, Nan-Yeong and Noh, Myung Hyun and Lee, Ju Young},
title = {Dual-mode CRISPRa/i for genome-scale metabolic rewiring in Escherichia coli},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {15},
doi = {10.1093/nar/gkaf818}
}
EUVIMED